VCU's Massey Receives $2.7M NIH Grant for Cannabis Pain Research

Federal Investment in Cannabinoid Pain Science

The NIH awarded VCU pharmacology researcher Aron Massey $2.7 million over five years to investigate cannabinoid receptor mechanisms in pain modulation. The grant, announced August 10, 2026, positions VCU among a handful of institutions receiving eight-figure federal cannabis research funding this fiscal year.

The award comes through NIH's National Institute on Drug Abuse, the agency's primary vehicle for cannabis pharmacology grants. NIDA has allocated $196 million to cannabinoid research in FY2026, up 14% from the prior year.

Research Focus and Clinical Implications

Massey's lab will examine how specific cannabinoid compounds interact with CB1 and CB2 receptors to reduce inflammatory pain signals. The study targets chronic pain conditions where opioid alternatives are urgently needed.

This work is preclinical validation for targeted cannabinoid therapies. If Massey's team identifies receptor-specific pathways, pharmaceutical developers gain a roadmap for non-intoxicating pain drugs.

VCU's Cannabis Research Infrastructure

Virginia Commonwealth operates one of 12 DEA-licensed facilities authorized to conduct Schedule I cannabis research with federal funding. VCU's Massey Cancer Center houses the cannabinoid pharmacology lab and a dedicated biosafety suite for controlled-substance work.

Since 2023, the university has received $11.3 million in NIH cannabis grants. Three concurrent studies are underway examining cannabinoids in cancer pain, PTSD, and neurodegenerative disease.

Federal Funding Landscape for Cannabis Science

NIH has awarded 47 cannabis-related grants totaling $287 million in 2026, the highest annual commitment on record. Most fund basic science rather than clinical trials.

NIDA, the National Cancer Institute, and the National Institute of Neurological Disorders and Stroke account for 89% of federal cannabis research dollars. For full background on this funding trend, see the CannIntel topic hub on NIH cannabis research grants.

Opioid Crisis Context

Federal agencies are prioritizing cannabinoid pain research as opioid overdose deaths exceeded 81,000 in 2025. The CDC reported a 3% year-over-year increase in opioid fatalities, sustaining pressure on Congress and HHS to fund alternative analgesics.

Massey's grant application cited data showing states with medical cannabis programs saw 6.5% lower opioid prescription rates. His study will test whether isolated cannabinoids replicate that effect in controlled conditions.

Timeline and Deliverables

The five-year grant runs through August 2031 with annual progress reviews by NIDA. Massey's team must publish interim findings by year three. Receptor-mapping work wraps by year four.

VCU will submit preliminary data to the FDA in 2029 if results warrant an investigational new drug application. That pathway remains theoretical; no NIH-funded cannabinoid study has yet advanced to Phase I trials.

What to Watch

Massey's protocol publication is expected in Q4 2026. That's the next milestone. NIDA will release its updated cannabis research priorities in September, signaling whether pain studies remain the agency's top funding category. Investor attention is on whether academic findings translate to commercial drug development or remain siloed in basic science.